Your feedback is important to us!
We invite all our readers to share with us their views and comments about this article.
Disclaimer: Comments submitted by third parties on this site are the sole responsibility of the individual(s) whose content is submitted. The Daily Star accepts no responsibility for the content of comment(s), including, without limitation, any error, omission or inaccuracy therein. Please note that your email address will NOT appear on the site.
Alert: If you are facing problems with posting comments, please note that you must verify your email with Disqus prior to posting a comment. follow this link to make sure your account meets the requirements. (http://bit.ly/vDisqus)
There's a simple but neglected solution to end the TB crisisIn an age of rapid technological innovation, it is shameful that almost 2 million people will die from tuberculosis this year because they are too poor to afford treatment. This indifference stems from the deadly delusion that TB is a disease of the past – a delusion that has persisted, even as 10.4 million people contracted TB in 2016 . TB patients are generally powerless to demand the world's attention. Multidrug-resistant TB is a serious threat.The treatment options for TB have scarcely evolved in decades. After 50 years without a single new TB drug being developed, two – bedaquiline and delamanid – were approved in quick succession.We took action because cash-strapped national TB programs tend to be conservative about adopting new treatments, and because pharmaceutical manufacturers have little incentive to bring their drugs to market in poorer countries.The evidence we have gathered so far indicates that when the new drugs are used, hard-to-treat TB patients are likelier to recover, and often do so more quickly.
FOLLOW THIS ARTICLE